When to Discontinue Losartan in CKD
Losartan should generally be continued throughout the course of CKD, even as eGFR declines below 30 ml/min/1.73 m², and should only be discontinued for specific clinical indications: serum creatinine rise >30% within 4 weeks of initiation/dose increase, uncontrolled hyperkalemia despite medical management, symptomatic hypotension, or to reduce uremic symptoms in advanced kidney failure (eGFR <15 ml/min/1.73 m²). 1
Continue Losartan in Most Circumstances
The 2024 KDIGO guidelines provide the most current evidence-based framework for ARB management in CKD. The default approach is continuation, not discontinuation. 1
Continue losartan when:
- eGFR falls below 30 ml/min/1.73 m² - This is explicitly stated as appropriate 1
- Serum creatinine rises by ≤30% within 4 weeks of starting or dose escalation 1
- Hyperkalemia is controllable with medical management (potassium binders, dietary modification, diuretics) 1
- Blood pressure remains adequate without symptomatic hypotension 1
The rationale is clear: ARBs remain nephroprotective even in advanced CKD stages, and their cardiovascular and renal benefits persist 1, 2.
Specific Indications for Discontinuation
1. Acute Creatinine Rise >30%
Discontinue or reduce dose if serum creatinine increases by more than 30% within 4 weeks following initiation or dose increase 1. This threshold distinguishes expected hemodynamic effects from true renal injury.
Monitor creatinine 2-4 weeks after starting or increasing losartan dose 1. The FDA label reinforces this, noting that drugs inhibiting the renin-angiotensin system can cause acute renal failure, particularly in volume-depleted patients or those with bilateral renal artery stenosis 3.
2. Uncontrolled Hyperkalemia
Consider discontinuation when hyperkalemia persists despite medical treatment 1. This is a critical qualifier - first attempt management with:
- Potassium binders
- Dietary potassium restriction
- Loop diuretics (if appropriate)
- Discontinuation of other potassium-sparing agents
Only discontinue losartan when these measures fail 1. The FDA label warns about hyperkalemia risk, particularly in CKD patients, and recommends periodic monitoring with potential dose reduction or discontinuation 3.
3. Symptomatic Hypotension
Reduce dose or discontinue if patient develops symptomatic hypotension 1. This means clinical symptoms (dizziness, syncope, falls), not just numerical blood pressure readings. Asymptomatic low blood pressure alone is not an indication to stop.
4. Advanced Kidney Failure (eGFR <15 ml/min/1.73 m²)
Consider discontinuation to reduce uremic symptoms while treating kidney failure 1. This is the only eGFR-based threshold mentioned, and even here it's "consider," not mandatory. The decision should be individualized based on whether the patient is approaching dialysis and whether uremic symptoms are present.
Temporary Discontinuation Scenarios
Temporarily withhold losartan during:
- Acute intercurrent illness with volume depletion 2
- Planned IV radiocontrast administration 2
- Bowel preparation prior to colonoscopy 2
- 48-72 hours before elective surgery 4
Critical caveat: Establish a clear plan for restarting losartan after these events, as failure to restart can lead to unintentional harm 4. Document this plan explicitly in the medical record and communicate it to the patient and other providers 4.
Monitoring Requirements
When continuing losartan in CKD:
- Check BP, serum creatinine, and potassium within 2-4 weeks of initiation or dose increase 1
- Frequency depends on current eGFR and baseline potassium 1
- Monitor periodically thereafter, especially during intercurrent illness 3
Special Populations Requiring Caution
While not absolute contraindications, exercise extreme caution and closer monitoring in:
- Bilateral renal artery stenosis or solitary kidney with stenosis - These patients are at high risk for acute renal failure 3, 5. Research shows losartan can cause transient anuria in this setting 5
- Severe volume depletion - Correct volume status before initiating losartan 3
- Severe heart failure with volume depletion - Renal function may be angiotensin-dependent 3
Common Pitfalls to Avoid
- Don't automatically discontinue when eGFR falls below 30 - This contradicts current guidelines 1
- Don't stop for hyperkalemia without attempting medical management first 1
- Don't forget to restart after temporary discontinuation - This is a major source of preventable harm 4
- Don't combine with ACE inhibitors or direct renin inhibitors - This combination is potentially harmful and not recommended 6, 7
Evidence Strength
The 2024 KDIGO guidelines 1 represent the highest quality, most recent evidence and should guide practice. These supersede older 2014 KDOQI commentary 2 where recommendations differ. The ACC/AHA hypertension guidelines 8, 6, 7 align with KDIGO regarding ARB use in CKD but focus more on hypertension management than CKD-specific considerations.